Effect of tocilizumab plus corticosteroid on clinical outcome in patients hospitalized with severe fever with thrombocytopenia syndrome: A randomized clinical trial

• Published in: The Journal of infection 2024-07, Vol.89 (1), p.106181, Article 106181
• Main Authors: Ge, Hong-Han, Cui, Ning, Yin, Xiao-Hong, Hu, Li-Fen, Wang, Zhi-You, Yuan, Yi-Mei, Yue, Ming, Lv, Hong-Di, Wang, Zhen, Zhang, Wen-Wen, Zhang, Lan, Yuan, Lan, Fan, Xue-Juan, Yang, Xin, Wu, Yong-Xiang, Si, Guang-Qian, Hu, Zhen-Yu, Li, Hao, Zhang, Xiao-Ai, Bao, Peng-Tao, Liu, Wei
• Format: Article
• Language: English
• Subjects: Case fatality rate; Corticosteroid; Randomized clinical trial; SFTS; Tocilizumab
• ISSN: 0163-4453; 1532-2742; 1532-2742
• DOI: 10.1016/j.jinf.2024.106181

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral hemorrhagic fever with high fatality rates. The blockade of pro-inflammatory cytokines presents a promising therapeutic strategy. We conducted a randomized clinical trial at the 154th hospital, Xinyang, Henan Province. Eligible patients with severe SFTS disease were randomly assigned in a 1:2 ratio to receive either a single intravenous infusion of tocilizumab plus usual care; or usual care only. The primary outcome was the clinical status of death/survival at day 14, while secondary outcomes included improvement from baseline in liver and kidney damage and time required for hospital discharge. The efficacy of tocilizumab plus corticosteroid was compared to those receiving corticosteroid alone. The trial is registered with the Chinese Clinical Trial Registry website (ChiCTR2300076317). 63 eligible patients were assigned to the tocilizumab group and 126 to the control group. The addition of tocilizumab to usual care was associated with a reduced death rate (9.5%) compared to those received only usual care (23.0%), with an adjusted hazard ratio (aHR) of 0.37 (95% confidence interval [CI], 0.15 to 0.91, P = 0.029). Combination therapy of tocilizumab and corticosteroids was associated with a significantly reduced fatality (aHR, 0.21; 95% CI, 0.08 to 0.56; P = 0.002) compared to those receiving corticosteroids alone. A significant benefit of reducing fatality in severe SFTS patients was observed by using tocilizumab. A combined therapy of tocilizumab plus corticosteroids was recommended for the therapy of severe SFTS. •Tocilizumab therapy can reduce the fatality for severe SFTS patients.•A combined therapy of tocilizumab plus corticosteroids was recommended for SFTS.•Patients treated with tocilizumab did not experience more serious coinfections.